New weight loss pill could replace needles: early human testing begins
NCT ID NCT07388667
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tests MK-4082, a new weight loss pill, in 120 healthy overweight or obese adults. Unlike current injectable weight loss drugs, this medicine is taken as a pill. The main goal is to check safety and how the body processes different doses, not yet to measure weight loss.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MK-4082 (oral tablet)
What this could lead to
If this pill is safe and works, it could lead to a new weight loss medicine taken as a pill instead of an injection.
What could go wrong
This is a very early Phase 1 study in healthy people, not yet testing weight loss. The drug may not work or could have side effects. Many early drugs fail.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anaheim Clinical Trials ( Site 0005)
Anaheim, California, 92801, United States
-
Bio-Kinetic Clinical Applications, LLD dba QPS-MO ( Site 0004)
Springfield, Missouri, 65802, United States
-
Hassman Research Institute Marlton Site ( Site 0006)
Marlton, New Jersey, 08053, United States
-
ProSciento Inc. ( Site 0002)
Chula Vista, California, 91911, United States
-
QPS-MRA, LLC ( Site 0003)
South Miami, Florida, 33143, United States